

Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS

Jun 03, 2016

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/novartis-data-show-gilenya-had-significantly-greater-patient-retention-compared-idmts-relapsing-remitting-ms-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-data-show-gilenya-had-significantly-greater-patient-retention-compared-idmts-relapsing-remitting-ms-0>